Want to see PVLA full AI Analyst Report?
PVLA Stock Chart & Stats
$130.01
-$0.34(-2.31%)
At close: 4:00 PM EST
$130.01
-$0.34(-2.31%)
Day’s Range― - ―
52-Week Range$21.55 - $161.38
Previous CloseN/A
Volume11.83K
Average Volume (3M)259.90K
Market Cap
$2.19B
Enterprise Value$1.13B
Total Cash (Recent Filing)$261.85M
Total Debt (Recent Filing)$584.00K
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Aug 13, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.17
Shares Outstanding14,342,844
10 Day Avg. Volume311,784
30 Day Avg. Volume259,898
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)42.09
Price to Sales (P/S)0.00
P/FCF Ratio-47.10
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-30.84
Forecast
1Y Price Target
$235.40Price Target Upside81.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-5.56
Revenue Forecast (FY)$26.67K
Bulls Say, Bears Say
Bulls Say
Strong Phase 3 Data & Regulatory DesignationsRobust SELVA Phase 3 results and multiple FDA designations materially lower clinical and regulatory risk for QTORIN. This supports a potential first-in-disease approval pathway, strengthens barrier to competition in rare vascular malformations, and improves long-term commercial prospects if approvals follow.
Rolling NDA Submission On TrackA rolling NDA filing is a structural regulatory milestone that de-risks the development timeline and advances commercialization readiness. Completing an NDA in H2 2026 would enable regulatory review and potential launch planning, materially changing the company’s operating profile from purely clinical to regulatory execution.
Strengthened Cash Position After Equity RaiseA large, recent equity financing meaningfully expands runway and funds NDA completion, launch readiness, and additional trials. With ~ $262M in cash, short-term solvency risk is reduced, allowing the company to invest in commercialization infrastructure and regulatory activities without immediate financing pressure.
Bears Say
No Current Product RevenueAs a clinical-stage biotech, Palvella lacks operating revenue and remains dependent on financing and milestone events. Until QTORIN (or another asset) achieves regulatory approval and generates sales, the business model offers no internal cash generation, leaving long-term sustainability contingent on successful commercialization.
Accelerating Cash BurnNegative operating and free cash flow that has accelerated to roughly -$29.1M TTM indicates rising funding needs. Even with recent financing, continued R&D, regulatory and commercial investments can exhaust resources before revenue ramps, increasing likelihood of future dilution or financing contingencies.
Limited Commercialization Scale & Small TeamWith a very small employee base and no prior commercial launches, Palvella faces material execution risk building sales, manufacturing, market access, and payer relationships. Scaling to a commercial organization or executing partnerships requires time, hiring, and investment that could strain resources during launch.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics, Inc.’s price range in the past 12 months?
Palvella Therapeutics, Inc. lowest stock price was $21.55 and its highest was $161.38 in the past 12 months.
What is Palvella Therapeutics, Inc.’s market cap?
Palvella Therapeutics, Inc.’s market cap is $2.19B.
When is Palvella Therapeutics, Inc.’s upcoming earnings report date?
Palvella Therapeutics, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 43 days.
How were Palvella Therapeutics, Inc.’s earnings last quarter?
Palvella Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.2 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.2.
Is Palvella Therapeutics, Inc. overvalued?
According to Wall Street analysts Palvella Therapeutics, Inc.’s price is currently Undervalued.
Does Palvella Therapeutics, Inc. pay dividends?
Palvella Therapeutics, Inc. does not currently pay dividends.
What is Palvella Therapeutics, Inc.’s EPS estimate?
Palvella Therapeutics, Inc.’s EPS estimate is -1.16.
How many shares outstanding does Palvella Therapeutics, Inc. have?
Palvella Therapeutics, Inc. has 14,342,844 shares outstanding.
What happened to Palvella Therapeutics, Inc.’s price movement after its last earnings report?
Palvella Therapeutics, Inc. reported an EPS of -$1.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.991%.
Which hedge fund is a major shareholder of Palvella Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$235.40 (81.06% Upside)
$235.40 (81.06% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 52.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
601.26%
12-Months-Change
Fundamentals
Return on Equity
-56.87%
Trailing 12-Months
Asset Growth
232.03%
Trailing 12-Months
Company Description
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q1 2026
0:00 / 0:00
PVLA Stock 12 Month Forecast
Average Price Target
$235.40
▲(81.06% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
―
Tyra Bioscience
―
Ownership Overview
1.92% Insiders
20.81% Mutual Funds
59.12% Other Institutional Investors
7.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---